Skip to main content
보도자료 배포 뉴스와이어
검색폼
검색
로그인
회원가입
보도자료
서비스
교육
블로그
보도자료 배포
보도자료 구독
고객센터
보도자료 배포 서비스
보도자료 배포 뉴스와이어
보도자료 배포
보도자료 구독
고객센터
로그인
회원가입
보도자료
서비스
교육
블로그
통합검색
보도자료
사진
동영상
기업
박람회
FAQ
취소
기업 검색
보도자료 등록
최신
IT
건강
경제
교육
금융
농수산
라이프
레저
문화
미디어
부동산
사회
산업
스포츠
에너지
운송
유통
자동차
정책
신상품
상장기업
주요
최신 보도자료
MY뉴스
상장기업
사진
동영상
기업뉴스룸
박람회
인기 토픽
보도자료 분야와 RSS
English News
산업별
IT
건강
경제
교육
금융
농수산
라이프 스타일
레저
문화/연예
미디어
산업별
부동산
사회
산업
스포츠
에너지/환경
운송
유통
자동차
정책/정부
주제별
개발
공모/모집
기업문화
부고
분양
사업계획
사회공헌
선언/의견
설립/오픈
소송
수상/선정
수주
주제별
신상품
실적
인물동정
인사
인수/합병
전시/출품
정책
제휴
조사연구
채용
투자
판촉활동
지역별
서울
인천/경기
대전/충남
광주/전남
부산/울산/경남
대구/경북
강원
충북
전북
제주
해외
기업 뉴스룸
Boehringer Ingelheim International GmbH
이 회사 보도자료 구독
제약
INGELHEIM, Germany
http://www.boehringer-ingelheim.com
Boehringer Ingelheim International GmbH 보도자료
337개
RSS
이메일
2018년 4월 17일
11:15
Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford to Investigate the Effects of Empagliflozin in People with Chronic Kidney Disease
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of ca
건강
제약
제휴
2018년 4월 12일
09:45
Boehringer Ingelheim to invest €65 million in avian vaccines
Six months after inaugurating its new French animal health headquarters in the heart of the Lyon-Gerland Biodistrict, Boehringer Ingelheim has confirmed its allegiance to the region by announcing that it is about to invest a further €65 million in th
건강
제약
사업계획
2018년 4월 5일
13:15
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, today announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172,
건강
제약
제휴
2018년 3월 30일
14:25
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine[1]
Boehringer Ingelheim today announced data from the landmark 52-week DYNAGITO® trial which show that in people with COPD (chronic obstructive pulmonary disease), Spiolto® Respimat® (tiotropium/olodaterol 5/5µg) lowers the rate of moderate-to-severe ex
건강
제약
개발
2018년 3월 27일
09:55
Three Leading Animal Health Companies Join Hands to Launch World-Class Vaccine Joint Venture Targeting Foot-and-Mouth Disease in China
Shaanxi Meili Omni-Honesty Animal Health Co., Ltd., China’s world-class vaccine company targeting foot-and-mouth disease in swine, was launched on March 24th with a groundbreaking ceremony held at the Airport New City in Xi’an, capital city of Shaanx
건강
제약
설립/오픈
2018년 3월 21일
13:05
Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis
New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIA™-AF, were presented at the EHRA 2018, the annual congress of
건강
제약
개발
2018년 3월 20일
11:30
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). The FDA’s Fast Track d
건강
제약
개발
2018년 3월 7일
13:25
Boehringer Ingelheim and Lilly expand heart failure programme for empagliflozin with new exercise capacity trials
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to expand their clinical trial programme for empagliflozin in chronic heart failure with the EMPERIAL clinical trials. These trials will evaluate the effect of empaglifl
건강
제약
개발
2018년 3월 6일
17:55
Boehringer Ingelheim Starts New Campaign: ‘Why wait in IPF?’
On Rare Disease Day, 28 February, Boehringer Ingelheim emphasises the question: ‘Why wait in IPF?´ while awareness activities are focussing on highlighting the benefits of early diagnosis and considering early treatment of idiopathic pulmonary fibros
건강
제약
조사연구
2018년 1월 4일
09:15
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€
Boehringer Ingelheim today announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million. The additional funds will be used to invest in promising early stage start
건강
제약
투자
2017년 12월 12일
09:30
Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017
2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer
건강
제약
제휴
2017년 11월 21일
10:10
Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential
Boehringer Ingelheim today announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most re
건강
제약
개발
2017년 11월 15일
18:35
Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy
Boehringer Ingelheim has shared sub-analyses from the RE-DUAL PCI™ clinical trial at the AHA Scientific Sessions 2017 in Anaheim, California. RE-DUAL PCI™ investigated different treatment approaches in patients with non-valvular atrial fibrillation (
건강
제약
조사연구
2017년 11월 15일
13:10
New RE-VERSE AD™ analyses provide additional insights on impact of Praxbind® (idarucizumab) in Pradaxa® (dabigatran etexilate) patients with gastrointestinal bleeding or needing emergency surgery
Boehringer Ingelheim announced results from two sub-analyses of the phase III RE-VERSE AD™ study.[1,2] The sub-analyses evaluated the safety and efficacy of idarucizumab (marketed as Praxbind®) in reversing the anticoagulant effect of dabigatran etex
건강
제약
조사연구
2017년 11월 14일
18:05
Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
New data showed that empagliflozin reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. These results, from a post-hoc analysis of the landmark EMP
건강
제약
조사연구
2017년 11월 14일
10:05
Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases
Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation for Cyltezo® a biosimilar to Humira® for the treatment of multiple chronic inflammatory diseases in adults and children.* “Cyltezo® is the first
건강
제약
개발
2017년 11월 9일
10:10
Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
Boehringer Ingelheim and MiNA Therapeutics (“MiNA”), a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver disease
건강
제약
제휴
2017년 11월 7일
15:20
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed that Cyltezo® is equivalent, with no clinically mean
건강
제약
개발
2017년 11월 3일
11:55
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced a research collaboration and license agreement to discover and develop novel GalXC™ RNAi ther
건강
제약
제휴
2017년 10월 31일
09:55
Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments to cancer patients by developing novel immuno-oncology therapies. The new effort combines Boehringer I
건강
제약
제휴
2017년 9월 19일
13:10
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’
IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.1 Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost. However, diagn
건강
제약
조사연구
2017년 9월 18일
16:45
CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in Pradaxa® Summary of Product Characteristics
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to the European Summary of Product Characteristics (SmPC) of Pradaxa® (dabigatran etexilate) for the treatmen
건강
제약
개발
2017년 9월 18일
11:00
Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorisation Application of Cyltezo® (ada
건강
제약
개발
2017년 9월 12일
15:00
Safety and efficacy results from the INJOURNEY™ trial investigating OFEV® (nintedanib) with add-on pirfenidone provide new data to support nintedanib’s key role in IPF
Results from the INJOURNEY™ trial, investigating the use of nintedanib in combination with pirfenidone in treating idiopathic pulmonary fibrosis (IPF), have just been published in the American Journal of Respiratory and Critical Care Medicine.[1] The
건강
제약
개발
2017년 8월 29일
17:40
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May
건강
제약
개발
이전
3
4
5
6
7
다음
동영상
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine
회사 보도자료 구독
뉴스와이어 회원은 이 회사 보도자료를 이메일과
MY뉴스
를 통해 무료로 구독할 수 있습니다.
회원 가입하기